Show simple item record

dc.contributor.advisorObikeze, Kenechukwu
dc.contributor.advisorChauke, Chesa Gift
dc.contributor.authorNgqaneka, Thobile
dc.date.accessioned2021-03-23T09:49:54Z
dc.date.available2021-03-23T09:49:54Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/11394/8016
dc.descriptionMagister Pharmaceuticae - MPharmen_US
dc.description.abstractCardiovascular diseases (CVDs) such as ischaemic heart diseases, heart failure and stroke remain a major cause of death globally. Various deep-rooted factors influence CVD development; these include but are not limited to elevated blood lipids, high blood pressure, obesity and diabetes. A considerable number of proteins are involved directly and indirectly in the transport, maintenance and elimination of plasma lipids, including high and low-density lipoprotein cholesterol (HDL-C and LDL-C). There are several mechanisms involved in the removal of LDL particles from systemic circulation. One such mechanism is associated with the gene that encodes proprotein convertase subtilisin/kexin type 9 (PCSK9), which has become an exciting therapeutic target for the reduction of residual risk of CVDs. Currently, statins are the mainstay treatment to reduce LDL-C, and a need exists to further develop more effective LDL-C-lowering drugs that might supplement statins.en_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectAtherosclerosisen_US
dc.subjectCardiovascular disease (CVD)en_US
dc.subjectHigh-density lipoprotein (HDL)en_US
dc.subjectLipidsen_US
dc.subjectLow-density lipoprotein (LDL)en_US
dc.titleThe impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)en_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record